explore -WSS

explore

author：hotspot 2025-09-03 05:40:06 - browse：49

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Nobel honors Karikó and Weissman's enduring partnership

leisure time

WSS

Apellis safety probe of eye disease drug centers on injection needle

CDC picks Alphabet's Verily for wasterwater surveillance contract

The Karikó problem: Lessons for funding basic research

Nobel honors Karikó and Weissman's enduring partnership

CDC advisory panel says seniors 'may' get RSV vaccine

FDA panel gives mixed vote on blood pressure devices

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

How Long Island became the ‘eugenics capital of the world’

Medical records are filled with copy

As pharma fights Medicare drug negotiation, hospitals, docs silent

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Drug repurposing or repositioning? The language matters

IVG is promising — but it won’t replace IVF quite yet

What does generative AI mean for health care? We asked experts

The biotech scorecard for Q4: 16 stock

hotspot

Apellis safety probe of eye disease drug centers on injection needle

What will Novo Nordisk's VC do with its influx of cash?

With Roe v Wade overturned, abortion providers work to adapt

AstraZeneca bets AAV gene therapy will still deliver the goods

CDC picks Alphabet's Verily for wasterwater surveillance contract

Will an HIV vaccine ever be a reality?

hotspot

hotspot

leisure time

Wikipedia